Meisner Lara 4

What Happened Lara Meisner, Chief Legal Officer of Bicara Therapeutics (BCAX), received a grant/award on Feb 2, 2026 consisting of 90,000 derivative shares/options. The filing shows $0 cash paid at grant (transaction coded as an award/acquisition), so this is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; filing date: 2026-02-04 (filed promptly).
• Transaction type: Award/Grant (code A); 90,000 derivative shares/options acquired; reported price $0.00.
• Vesting: Footnote states the shares underlying this option vest in 16 equal quarterly installments beginning Feb 2, 2026, contingent on continued service.
• Shares owned after transaction: not disclosed in the excerpt provided.
• No immediate sale or exercise reported — this is a grant that vests over time.

Context This is a typical equity compensation award for an executive and does not represent a cash purchase or sale. For derivative grants like options, future value depends on vesting and any exercise price (not shown here); the grant aligns the executive’s compensation with future company performance.